Matthew Taylor
Stock Analyst at UBS
(2.68)
# 2,148
Out of 5,050 analysts
182
Total ratings
60%
Success rate
10.94%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Neutral | $320 → $355 | $319.82 | +11.00% | 16 | Nov 7, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $80 → $98 | $83.39 | +17.52% | 20 | Oct 29, 2025 | |
| SI Shoulder Innovations | Initiates: Buy | $19 | $11.05 | +71.95% | 1 | Aug 25, 2025 | |
| ABT Abbott Laboratories | Upgrades: Buy | $143 → $145 | $126.36 | +14.75% | 17 | Jul 18, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $14.45 | +3.81% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $73.05 | +41.00% | 2 | Jan 8, 2025 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $92.20 | -17.57% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $1.55 | +7,964.52% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $143.20 | -15.50% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $3.81 | +267.45% | 1 | Jan 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $45 | $16.26 | +176.75% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $10 | $6.01 | +66.39% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $12.04 | +340.20% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $11.97 | +100.50% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $356.03 | -3.10% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $88.50 | +46.89% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $266.19 | -13.60% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $15.77 | +26.82% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $43.97 | +93.31% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $83.89 | -10.60% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $251.49 | -2.58% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $18.00 | +244.44% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $109.40 | +91.96% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $19.80 | -39.39% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $55.00 | +127.27% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $100.02 | -50.01% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $560.00 | -62.50% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $50.45 | +90.29% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $2.23 | +213.90% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $177.84 | +49.57% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $12.02 | +33.11% | 2 | Jul 19, 2017 |
Insulet
Nov 7, 2025
Maintains: Neutral
Price Target: $320 → $355
Current: $319.82
Upside: +11.00%
Edwards Lifesciences
Oct 29, 2025
Upgrades: Buy
Price Target: $80 → $98
Current: $83.39
Upside: +17.52%
Shoulder Innovations
Aug 25, 2025
Initiates: Buy
Price Target: $19
Current: $11.05
Upside: +71.95%
Abbott Laboratories
Jul 18, 2025
Upgrades: Buy
Price Target: $143 → $145
Current: $126.36
Upside: +14.75%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $14.45
Upside: +3.81%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $73.05
Upside: +41.00%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $92.20
Upside: -17.57%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $1.55
Upside: +7,964.52%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $143.20
Upside: -15.50%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $3.81
Upside: +267.45%
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $16.26
Upside: +176.75%
Jul 19, 2023
Initiates: Underperform
Price Target: $10
Current: $6.01
Upside: +66.39%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $12.04
Upside: +340.20%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $11.97
Upside: +100.50%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $356.03
Upside: -3.10%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $88.50
Upside: +46.89%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $266.19
Upside: -13.60%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $15.77
Upside: +26.82%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $43.97
Upside: +93.31%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $83.89
Upside: -10.60%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $251.49
Upside: -2.58%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $18.00
Upside: +244.44%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $109.40
Upside: +91.96%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $19.80
Upside: -39.39%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $55.00
Upside: +127.27%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $100.02
Upside: -50.01%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $560.00
Upside: -62.50%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $50.45
Upside: +90.29%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $2.23
Upside: +213.90%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $177.84
Upside: +49.57%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $12.02
Upside: +33.11%